Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebrovascular disorder17.08.02.002; 24.03.05.002--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.001444%Not Available
Chills15.05.03.016; 08.01.09.001--
Chronic obstructive pulmonary disease22.03.01.0070.000784%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.001872%Not Available
Condition aggravated08.01.03.0040.003138%Not Available
Confusional state19.13.01.001; 17.02.03.0050.002674%
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.000178%Not Available
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.006--Not Available
Crohn's disease07.08.01.015; 10.02.01.0050.000267%Not Available
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.005527%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.000267%
Dementia19.20.02.001; 17.03.01.0010.000535%Not Available
Dependence19.07.06.0080.000392%Not Available
Depressed mood19.15.02.0010.003619%Not Available
Depression19.15.01.0010.012730%
Derealisation19.10.05.0040.000392%Not Available
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.000267%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.000784%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000178%Not Available
Distractibility19.21.02.0070.000392%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.001783%
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.0060.013657%
Drug abuse19.07.06.010--Not Available
Drug dependence19.07.06.011--Not Available
Drug hypersensitivity10.01.01.0010.014264%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages